MediPaper Hong Kong

Medical Communications MediNews

Therapeutic Areas

IMMUNO-ONCOLOGY ARTICLES

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

May 10, 2018/by Stijn van den Borne, MSc

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

First-line atezolizumab plus bevacizumab, carboplatin and paclitaxel improves PFS in patients with non-squamous NSCLC. Two presentations on the IMPower150 study by Martin Reck (ELCC 2018) and Mark Socinski (AACR 2018) discussed the frontline addition of atezolizumab to bevacizumab and chemotherapy in different lung cancer subgroups (NCT02366143).

US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

May 2, 2018/by Stijn van den Borne, MSc

US FDA approved CAR-T cell and BiTE immunotherapy - Updated 2-May-2018

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

April 23, 2018/by Stijn van den Borne, MSc

U.S. FDA Approved Immune-Checkpoint Inhibitors Updated 23-Apr-2018

AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826

Hywards / 123RF Stock Photo

April 21, 2018/by Stijn van den Borne, MSc

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

krishnacreations / 123RF Stock Photo

April 19, 2018/by Stijn van den Borne, MSc

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

ONCOLOGY ARTICLES

Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

April 10, 2018/by Stijn van den Borne, MSc

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab (Keytruda®) as single-agent immunotherapy in the frontline setting of any histology NSCLC with a PD-L1 expression ≥1% was associated with improved overall survival (OS) when compared to platinum-doublet chemotherapy in the KEYNOTE-042.

Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

April 6, 2018/by Stijn van den Borne, MSc

I-O in Special Populations: Diabetes and Concomitant Steroids

Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

April 4, 2018/by Stijn van den Borne, MSc

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

March 31, 2018/by Stijn van den Borne, MSc

Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

Making sense of immunotherapy in NSCLC

March 26, 2018/by Stijn van den Borne, MSc

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

CONFERENCE HIGHLIGHTS

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

© European Society for Medical Oncology

ASCO 2016 annual meeting

©American Society of Clinical Oncology

©American College of Cardiology

ONCOLOGY ARTICLES (Cont’d)

Symposium Highlight 5HT3 NK1 Palonosetron Netupitant CINV Chemotherapy-induced Nausea and Vomiting

January 30, 2018/by Stijn van den Borne, MSc

Advances in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: From Multi-Dose to Single Dose Control

How to optimise the prevention of chemotherapy-induced nausea and vomiting (CINV) utilising a 5HT3 RA and NK1 RA? Learn more about the combination of palonosetron, a 5HT3 RA, plus netupitant, an NK1 RA.

manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

November 29, 2017/by Stijn van den Borne, MSc

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

November 20, 2017/by Stijn van den Borne, MSc

Do you know your lifetime risk on Pancreatic Cancer?

HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

October 25, 2017/by Stijn van den Borne, MSc

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

Nivolumab Renal Cell Cancer Symposium Highlight

September 19, 2017/by Stijn van den Borne, MSc

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

Latest global trends of health measure and impact on survival rate

August 16, 2017/by Stijn van den Borne, MSc

Latest global trends of health measure and impact on survival rate

Lack of strength and diabetes are becoming epidemic in the ageing population, and patients often ignore early signs and are unaware how to prevent these problems.

scientific symposium highlights optimisation of aerosol delivery in patients with poor asthma control aerosol delivery asthma

July 18, 2017/by Stijn van den Borne, MSc

Optimisation of aerosol delivery in patients with poor asthma control

AMNOG Germany Pharmaceuticals Pricing Legislation MediPaper Medical Writer Hong Kong

December 15, 2016/by Stijn van den Borne, MSc

AMNOG: Germany Pharmaceuticals Pricing Legislation Overview

asco 2016 nivolumab medipaper medical communications

May 29, 2016/by Stijn van den Borne, MSc

ASCO16 Nivolumab (Opdivo©) Data

asco 2016 immune checkpoint inhibitors

April 4, 2016/by Stijn van den Borne, MSc

ACC2016: 8½ Important Cardiology Lessons Learned

May 16, 2018/by News Feed

Biosimilar epoetin alfa-epbx approved by FDA for the treatment of anemia due to chronic kidney disease, use of zidovudine for HIV, and concomitant myelosuppressive chemotherapy

©aquir / 123RF Stock Photo

May 4, 2018/by News Feed

FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation

US FDA Oncology Haematology Drug Approvals

©aquir / 123RF Stock Photo

May 1, 2018/by News Feed

Tisagenlecleucel CAR-T receives additional FDA Approval for DLBCL

©aquir / 123RF Stock Photo

April 30, 2018/by News Feed

FDA granted regular approval to dabrafenib and trametinib in combination for the adjuvant treatment of patients with BRAF V600E or V600K melanoma

©aquir / 123RF Stock Photo

April 19, 2018/by News Feed

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

©aquir / 123RF Stock Photo

April 17, 2018/by News Feed

FDA approved fostamatinib disodium hexahydrate tablets for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP)

©aquir / 123RF Stock Photo

April 16, 2018/by News Feed

FDA granted approvals to nivolumab plus ipilimumab for the treatment of intermediate or poor risk, previously untreated advanced RCC

Do you like our Medical Communications Blog? Sign up for the MediPaper newsletter!

© Copyright - MediPaper Medical Communications - Medical Communications Blog